Probiotic arginolytic oral compositions and methods of making and using probiotic arginolytic oral compositions
View Patent ↗The present disclosure provides methods of using probiotic arginolytic oral compositions including isolated arginolytic bacterial strains to increase arginolytic activity in the oral cavity, increase ammonia-producing bacteria in the oral cavity, and/or to treat and/or prevent oral disorders, such as caries.
1. A method of increasing the amount of ammonia-producing bacteria in the oral cavity of a host, the method comprising:
administering to a host a probiotic oral composition comprising:
a mixture of isolated bacterial strains, the mixture comprising at least two different isolated arginolytic bacterial strains, each strain capable of producing ammonia via the arginine deiminase system (ADS) and each strain meeting at least one of the following criteria: expressing ADS activity in the absence of supplemental arginine, expressing ADS activity in the presence of glucose, expressing ADS activity in a non-acidic pH, expressing ADS activity under aerobic conditions, inhibiting the growth of at least one bacterial strain associated with dental caries, and resisting inhibition of growth by at least one bacterial strain associated with dental caries, wherein the ability of the isolated arginolytic bacterial strain to express ADS activity under any of said criteria is determined with respect to an ADS activity level of S. gordonii DL1 under the same conditions, wherein an ADS activity level about the same or higher than the ADS activity of S. gordonii DL1 under the same conditions indicates the strain meets the criteria; and
a pharmaceutically acceptable oral carrier,
wherein at least two of the criteria are met by the mixture of bacterial strains at an ADS activity level greater than the ADS activity level of S. gordonii DL1 under the same conditions,
wherein the composition does not include Streptococcus mutans and does not include strains of bacteria from any other bacterial species associated with dental caries, and
wherein administration of the probiotic oral composition increases the amount of ammonia-producing bacteria in the oral cavity of the host over the amount of ammonia-producing bacterial in the oral cavity of the host prior to administration of the probiotic oral composition.
2. The method of claim 1 , wherein the bacterial strain associated with dental caries is Streptococcus mutans.
3. The method of claim 1 , wherein the probiotic oral composition further comprises one or more compounds capable of increasing the ADS activity of the bacterial strains with respect to the ADS activity of the strains in the absence of the compounds.
4. The method of claim 3 , wherein the compound to increase the ADS activity of the bacterial strains is arginine.
5. The method of claim 1 , wherein the mixture comprises: at least one arginolytic bacterial strain capable of expressing ADS activity in the absence of supplemental arginine, at least one arginolytic bacterial strain capable of expressing ADS activity in the presence of glucose, at least one arginolytic bacterial strain capable of expressing ADS activity in a non-acidic pH, at least one arginolytic bacterial strain capable of expressing ADS activity under aerobic conditions, and at least one arginolytic bacterial strain capable of inhibiting the growth of at least one bacterial strain associated with dental caries or capable of resisting inhibition of growth by at least one bacterial strain associated with dental caries.
6. The method of claim 1 , wherein at least one of the isolated arginolytic bacterial strains comprises Streptococcus A12.
7. A method of increasing the amount of ammonia-producing bacteria in the oral cavity of a host, the method comprising:
administering to a host a probiotic oral composition comprising:
a mixture of isolated bacterial strains, the mixture comprising: an isolated arginolytic bacterial strain Streptococcus A12 and at least one other isolated arginolytic bacterial strain capable of producing ammonia via the arginine deiminase system (ADS) and meeting at least one of the following criteria: expressing ADS activity in the absence of environmental arginine, expressing ADS activity in the presence of glucose, expressing ADS activity in a non-acidic pH, expressing ADS activity under aerobic conditions, inhibiting the growth of at least one bacterial strain associated with dental caries, and resisting inhibition of growth by at least one bacterial strain associated with dental caries; and
a pharmaceutically acceptable oral carrier.
8. The method of claim 7 , wherein the probiotic oral composition further comprises one or more compounds capable of increasing the ADS activity of the bacterial strains with respect to the ADS activity of the strains in the absence of the compounds.
9. The method of claim 8 , wherein the compound to increase the ADS activity of the bacterial strains is arginine.
10. A method of treatment comprising:
administering to a host a probiotic oral composition comprising an isolated arginolytic bacterial strain Streptococcus A12.
11. The method of claim 10 , wherein the probiotic oral composition further comprises one or more compounds capable of increasing the ADS activity of Streptococcus A12 with respect to the ADS activity of Streptococcus A12 in the absence of the compounds.
12. The method of claim 11 , wherein the compound to increase the ADS activity of the bacterial strains is arginine.
13. A method of preventing the incidence of dental caries, reducing the incidence of dental caries, slowing or arresting the progression of dental caries lesions, or a combination of these in a host, the method comprising:
administering to a host a probiotic oral composition comprising:
a mixture of isolated bacterial strains, the mixture comprising at least two different isolated arginolytic bacterial strains, each strain capable of producing ammonia via the arginine deiminase system (ADS) and each strain meeting at least one of the following criteria: expressing ADS activity in the absence of environmental arginine, expressing ADS activity in the presence of glucose, expressing ADS activity in a non-acidic pH, expressing ADS activity under aerobic conditions, inhibiting the growth of at least one bacterial strain associated with dental caries, and resisting inhibition of growth by at least one bacterial strain associated with dental caries, wherein the ability of the isolated arginolytic bacterial strain to express ADS activity under any of said criteria is determined with respect to an ADS activity level of S. gordonii DL1 under the same conditions, wherein an ADS activity level about the same or higher than the ADS activity of S. gordonii DL1 under the same conditions indicates the strain meets the criteria; and
a pharmaceutically acceptable oral carrier,
wherein at least two of the criteria are met by the mixture of bacterial strains at an ADS activity level greater than the ADS activity level of S. gordonii DL1 under the same conditions,
wherein the composition does not include Streptococcus mutans and does not include strains of bacteria from any other bacterial species associated with dental caries.
14. The method of claim 13 , wherein the probiotic oral composition further comprises arginine.
15. The method of claim 13 , wherein the bacterial strain associated with dental caries is Streptococcus mutans.